paradigm
BIOPHARMA

Investor Presentation

Paul Rennie, CEO & MD

November 2017



Disclaimer

This document, together with any information communicated by Paradigm Biopharmaceuticals Ltd (known as “Paradigm”, “Paradigm Biopharma” or “the Company”), in any presentation or discussion relating to this document (collectively, “Information”) is confidential, and has been prepared by the Company on the condition that it is for the exclusive information and use of the recipient. The Information is proprietary to Paradigm and may not be disclosed to any third party or used for any other purpose without the prior written consent of the Company.

The Information is based upon management forecasts and reflects prevailing conditions, which are accordingly subject to change. In preparing the Information, the Company has relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources, or which was otherwise reviewed by it. In addition, the analyses are not and do not purport to be appraisals of the assets, stock or business of the Company. Even when the Information contains a kind of appraisal, it should be considered preliminary, suitable only for the purpose described herein and should not be disclosed or otherwise used without the prior written consent of Paradigm. The Information is provided on the understanding that unanticipated events and circumstances may occur which may have significant valuation and other effects.

Corporate Overview

- Paradigm Biopharmaceuticals Ltd is an ASX-listed biotechnology company focused on repurposing pentosan polysulfate sodium (PPS), an **FDA-approved drug** that has a **long track record** of safely treating inflammation.
- Paradigm is repurposing PPS for a number of applications with a focus on treatment of **orthopaedic and viral arthritic** indications.
- Drug repurposing uses the 505(b)(2) pathway - **lower cost, minimises risk** and has accelerated development timelines.
- **Several clinical indications** such as Osteoarthritis/Bone Marrow Edema Lesions, Ross River virus and Chikungunya, giving us **"multiple shots on goal."**
- Strategy is to **establish commercial partnerships** with multiple leading pharmaceutical companies.

Financial information

Share price (01-November-17)	A$0.36
Number of shares	101.9m
Market capitalisation	**A$37.7m**
Cash (30-Sept-17) – no debt	~A$2.2m
Enterprise value	**A$34.5m**

Top shareholders[1,2]	Shares (m)	%
Paul Rennie *(Managing Director)*	21.5	21.1%
MJGD Nominees *(technology vendor)*	6.9	6.8%
Other Board and management	7.1	7.0%
Irwin Biotech *(technology vendor)*	6.3	6.2%

Note: 1. Blue shading represents Board and management holdings 2. MJGD Nominees and Irwin Biotech are select vendors of Xosoma, which was acquired by Paradigm prior to listing

Investment Proposition

- **Reduce clinical costs and accelerate commercialisation** by repurposing a pre-approved drug - **505(b)(2)**
- **Very large addressable markets (combined US$37bn+)** - Pentosan Polysulfate Sodium (PPS) is a new, multi-acting treatment for osteoarthritis (associated with bone lesions/bruising), viral arthritis, heart failure and respiratory conditions
- **Several clinical indications:** reduces clinical development risk and gives Paradigm **"multiple shots on goal"**
- **Highly credentialed board and management team** with top tier experience at CSL Limited (CSL.ASX) and Mesoblast Limited (MSB.ASX)
- **Fast-track time to market** through multi-faceted IP strategy and ability to leverage relationships
- **Strong focus on prudent cash management** to enhance shareholder returns
- **Several major clinical trial and development catalysts** expected over the next 12 months
- **High impact partnering opportunities** – Osteoarthritis, viral arthritis and inflammatory bowel disease all have large unmet clinical need for safe treatments

Drug Repurposing Strategy

Much lower cost, accelerated timeline, lower risk and with higher rates of success

- **Lower cost:** average development cost of ~US$30-50m compared to US$1.3bn for "de novo" development[1]
- **Faster:** FDA 505(b)(2) pathway leveraging previous clinical efforts**,** which accelerates the development timeline
- **Lower risk:** safety already established so less chance of failure (safety issues account for 30% of clinical failures[1])
- **Higher success rates:** 25% chance of successful commercialisation compared to 10% for "de-novo" drugs[1]
- **Repurposed drugs have the same potential** to reach 'blockbuster drug status' as de novo drugs

Standard clinical development[1,2]

10-17 year process

Discovery & pharmacology	Preclinical testing	Phase I clinical trials	Phase II clinical trials	Phase III clinical trials	Regulatory approval
2 – 3 years	5 – 6 years		2 – 6 years		1 – 2 years

Paradigm's drug repurposing timeline

3-5 year process to approval

Often only 1 pivotal Phase II trial Can use RWE open label case studies	1 pivotal Phase III trial for each indication	Regulatory approval
1 year	1 – 2 years	1 – 2 years

Source:
1. Khanaoure A, Chuki P & De Sousa A (2014)
2. Ashurn T & Thor K (2004)

Board and Management

High quality Board and management, with top-tier pharmaceutical experience

- Board and management are renowned leaders in the biopharmaceutical industry, having held senior management positions with top ASX-listed companies, CSL (CSL.ASX) and Mesoblast (MSB.ASX)
- Extensive experience bringing biopharmaceutical products from clinical development to commercialisation
- Small and highly specialised team focused on product development utilising outsourcing effectively

Board and management

Graeme Kaufman – Non-executive Chairman
- Broad experience in development and commercialisation of pharmaceutical drugs, previously CFO at CSL, executive VP of Mesoblast and Chairman of Bionomics (BNO)

Paul Rennie – Managing Director
- Extensive experience in drug development and commercialisation, previously COO & Executive VP, New Product Development of Mesoblast

John Gaffney – Non-executive Director
- 30+ years experience as a lawyer, previously Director of Patrys (PAB.ASX)

Christopher Fullerton – Non-executive Director
- Chartered Accounting and investment banking expertise, previously Non-executive Chairman of Bionomics and Cordlife (now Life Corporation (LFC.ASX))

Dr Ravi Krishnan – Chief Scientific Officer
- Significant experience in experimental pathology and investigating novel compounds with immune modulatory effects and anti-inflammatory properties

Kevin Hollingsworth – CFO & Company Secretary
- Previously CFO and Co-Sec of Mesoblast and Patrys (PAB.ASX)

Broad Product Pipeline

Drug Candidate	Indication(s)	Preclinical	SAS Pilot/Phase 1	Phase 2	Milestones (next 12 months)
Orthopaedic - Bone Marrow Edema/Lesions (Bone Bruising)					
PPS	BME with acute injuries (ACL etc)			~10 ACL Patients	ACL-BME Phase 2a results read out
	BME with Osteoarthritis (OA) - placebo controlled			100 OA patients	Commenced Phase 2b BME/OA Trial
	BME with Osteoarthritis (OA) - RWE Open Label		100 OA patients Open Label/RWE		25 patient groups reported qrtly
Viral Arthritis – Alphavirus					
PPS	Ross River Virus (RRv)		30 SAS RRv Patients	24 RRv Patients	Complete Phase 2
	Chikungunya virus (CHIKV)				Enter Phase 2 + other pilot studies
Respiratory					
PPS	allergic rhinitis (hay fever)		20 Phase 1 safety	40x2 patient crossover	Analyse trial data and reformulate
	Chronic Obstructive Pulmonary Disease (COPD)				Develop formulation & partner
	allergic asthma				Develop formulation & partner
Cardiovascular					
PPS	heart failure				Conduct 24 person placebo controlled Phase 1/2
Inflammation & autoimmune					
Novel Anti IL-1 RA inhibitor peptide	auto-immune disorders (IBD, Crohns' disease, GVHD), oncology, complications from cytotoxic drugs (mucositis) and cancer cachexia		26 patients phase 1/2		Reformulate into oral compound Finalise data pack & partner or progress human clinical trials

Pentosan Polysulfate Sodium

PPS has a long safety history and is currently being sold in the US and Europe

Pentosan Polysulfate Sodium

- Pentosan Polysulfate Sodium (PPS) has been used in humans for more than 60 years
- First approved by FDA more than 30 years ago
- Since approval, there have been in excess of 100 million injectable doses of PPS administered
- Paradigm has been granted patents to use PPS for new indications

Current treatment uses

- The oral formulation is FDA approved and sold under the name Elmiron, by Janssen Pharmaceuticals, for the treatment of interstitial cystitis (painful bladder syndrome)
- Also used to treat deep vein thrombosis

Ideal biological characteristics

- PPS is an anti-inflammatory and an anti-histamine with biological characteristics that make it ideally suited for treating hay fever (allergic inflammation in the nasal passage) and bone marrow edema lesions (inflammation in the bone) & viral arthritis
  - ✓ Anti-inflammatory
  - ✓ Anti-histamine
  - ✓ Anti-clotting
  - ✓ Prevents necrosis (premature cell death)
  - ✓ Prevents cartilage degeneration



Osteoarthritis and acute joint injuries with BMEL

Currently no approved treatments for Osteoarthritis growing market opportunity

What are bone marrow edema lesions (BMEL or bone bruising)?

- **Bone marrow edema lesions or bone bruising** is the accumulation of interstitial fluid or inflammation within the bone marrow, typically a consequence of a direct impact to bone.
- **BMEL are commonly associated with OA** and have been **linked to early onset of OA** and joint cartilage degeneration.[1]
- **Osteoarthritis** is the most common form of arthritis, affecting over **27 million people** in the United States, with over 36 million outpatient visits and 750,000 hospitalisations per year.[2]

OA Market Facts:

Market of therapeutics to treat OA

~US$5 billion pa Globally[3]

Cost to US Economy

US$128+ billion pa[4]

Andrew Walker - Carlton Football Club
200+ game player with severe knee pathologies resolved with PPS



Addressable market based on acute traumatic injuries:

1.4 million
knee & ankle injuries associated with bone bruising[5,6,7]

US$1,750
potential price per ZILOSUL® treatment

US$2.5+ billion
ZILOSUL® market in USA

Source:
1. The occurrence and progression of BMLs have been shown to be associated with progression to osteoarthritis and joint pain (Osteoarthritis and Cartilage 2012, 20:1514-1518) and (Rheumatology 2010, 49:2413-9).
2. http://ard.bmj.com/content/annrheumdis/early/2017/07/12/annrheumdis-2017-211396.full.pdf
3. National Institute of Health; Emerging drugs for osteoarthritis; Hunter DJ and Matthews G 16(3): 479–491; 2011 September.
4. *Ibid.*
5. Based on 200k ACL injuries per annum, with 80% being associated with BMEL – Niall D, et al. (2004) and Friedberg R, et al. (2016)
6. Based on 1m meniscal injuries per annum, with 80% assumed as being associated with BMEL – Jones C, et al. (2012)
7. Based on 600k ankle injuries per annum, with 80% assumed as being associated with BMEL – Waterman B, et al. (2010)

Osteoarthritis with BMEL: The Market for ZILOSUL®

ZILOSUL® has the potential to fill the current gap in osteoarthritis treatment options

- There is currently no effective treatment for osteoarthritis and bone marrow edema lesions that treats the underlying pathology of the disease.
- Current therapies treat the symptoms of osteoarthritis and bone marrow edema lesions but prolonged use results in undesirable side-effects. It is widely accepted that NSAIDs and corticosteroids are contraindicated having a detrimental effect on the metabolism of bone and cartilage.
- Opioid's are widely misused globally as patients form serious addictions whilst mitigating pain.[1]
- ZILOSUL® treats the underlying pathology of osteoarthritis by reducing inflammation, resolving the bone marrow edema lesions and down regulating cartilage degrading enzymes (MMP's and ADAMTS-5).

	paradigm (ZILOSUL®)	NSAID (ibuprofen etc)	Opioid (oxycodone etc)	Corticosteroid / Cortisone	Joint Replacement
Treats the symptoms of OA (pain & function)	✓	✓	✓	✓	✓
Treats underlying pathology	✓				✓
No undesirable side-effects	✓				
Non-addictive	✓	✓		✓	✓
Anti-inflammatory	✓	✓		✓	
Non-Surgical	✓	✓	✓	✓	

1. https://www.drugabuse.gov/news-events/news-releases/2017/07/pain-relief-most-reported-reason-misuse-opioid-pain-relievers

Osteoarthritis with Bone Marrow Edema Lesions

TGA Special Access Scheme – Real World Evidence – First 24 patients treated

All patients (median age of 57.5 years - range 31 to 84 years) had pain and failed current standard of care - analgesics, NSAIDs or corticosteroids.

At six weeks after the initiation of PPS treatment:

Pain

- 20 out of 24 patients (83.3%) showed a reduction in pain;
- 15 of the 20 responders (75%) showed a pain reduction of 50% or more.

Function

- 19 out 24 patients (79.1%) showed an improvement in knee function;
- 9 of the 19 responders (47.3%) showed an improvement in knee function scores of 50% or more.

Patient A MRI – Pre PPS Treatment



Pre treatment Scores

- High NRS Pain Score = **8**
- Lysholm Score: **37 (Poor knee function)**

BME Lesions (yellow arrows)
Joint Space Effusions (red arrows)

Patient A MRI – Post PPS Treatment



Post Treatment Results

- **Complete resolution** of BME lesions and effusions
- Pain NRS = **0 (pain resolved)**
- Lysholm Score: **65 (Fair knee function)**

OA with BMEL: Clinical Timeline

Status update

- **OA/BMEL case study published in peer reviewed scientific journal**
- **10 participants treated under the Phase 2a open label clinical trial - close-out expected Oct/Nov 2017**
  - Trial investigating the safety, tolerability and efficacy of ZILOSUL® in patients with a bone marrow edema lesions from a recent ACL (acute knee) injury
- **25 additional patients treated under the TGA SAS scheme. Very positive clinical signals from BMEL patients with osteoarthritis (OA) – plan to release 3 x 25 patient groups showing Real World Evidence over next 12 months**
- **Plan to undertake pilot studies in BMEL patients with rheumatoid arthritis (RA)**
- **Commence recruitment of Phase 2b placebo controlled (100 patient) clinical trial for BMEL with OA**



Note:
1. Closed label, randomised, double blind, placebo controlled trial expected to commence in Q42017, expected to be completed in 12-18 months after commencement

Viral Arthritis – Alphavirus

No approved treatment for severely debilitating virus infection

Viral Arthritis

- Alphavirus infections result in the clinical symptoms of joint and muscle pain, fever and joint inflammation.
- Ross River Virus (RRV) and Chikungunya (CHIKV) are mosquito-transmitted arthritogenic alpha viruses that cause epidemics of severe musculoskeletal disease in many countries.
- No effective treatment, with sufferers left incapacitated
- Symptoms can persist for a number of years

Ross River Virus & Chikungunya Virus

- Paradigm acquired the patent from the Institute for Glycomics research at Griffith University.
- The patent claims the use of PPS to treat alphaviruses, including Ross River Virus (RRV) and Chikungunya Virus (CHIKV).
- Potential interest from the **US Department of Defense** to co-develop for treating CHIKV



Chikungunya cases ,USA

Viral Arthritis: Clinical Timeline

Potential to gain Orphan status, resulting in fast-tracked clinical development

- **Pre-clinical studies have been conducted by the Institute of Glycomics at Griffith University. The results suggested that:**
  - PPS significantly alleviated the severity of disease and reduced both the inflammatory response and the loss of articular cartilage;
  - PPS has the potential to treat both acute and chronic symptoms associated with mosquito transmitted alphavirus infections (Ross River virus (RRV) and chikungunya virus (CHIKV);
  - There currently is no effective disease modifying treatment for RRV or CHIKV.
- 30 patients with RRV-arthralgia (joint pain) already treated with PPS under the TGA Special Access Scheme demonstrating tolerability and potential clinical effects
- **Phase 2 Clinical Trial – PPS to treat RRV and CHIKV**
  - Queensland Government have provided a A$300,000 grant for Ross River research
  - Paradigm to embark on two Phase 2 clinical trial to develop PPS for the treatment of RRV-and CHIKV-induced arthritis and arthralgia – **Potential for Fast-Track /Breakthrough/Accelerated Approval**



IL-1RA Peptide

Safe and Stable Treatment for Multiple Indications

What is IL-1RA Peptide?

- Vended in during the Initial Public Offering
- A novel IL-1RA peptide antagonist ("**IP1510**"), consists of D-amino acids with reversed peptide sequence (a retro-inverso peptide)
- Demonstrates antagonistic activity by inhibiting signal transduction and has higher stability suitable for a gastrointestinal product in comparison to the Human recombinant IL-1RA
- **Safety and efficacy confirmed in Phase 1/2 Clinical Trial (n:26)** of IP-1510 in the management of cancer-related cachexia (subcutaneous)
- IP1510 showed a reduction in IL-1a-induced IL-8 and IL-17 production in colonic epithelial cells
- Paradigm is reformulating into oral compound for which there is known big pharma partnering interest

Potential treatment for:

- Inflammatory bowel disease ("**IBD**")
- Cancer-related cachexia
- Ulcerative colitis
- Distal colitis
- Crohn's disease

Inflammatory Bowel Disease

World Market for Inflammatory Bowel Disease Medicines predicted to reach

US$9.3 Billion[1]

Big Pharma Interest

Janssen Biotech & Protagonist Therapeutics licensing deal to co-develop & commercialise Protagonist's oral peptide for treatment of IBD for

US$990 Million[2]

1. https://www.visiongain.com/Press_Release/932/The-World-Market-For-Inflammatory-Bowel-Disease-Medicines-will-reach-9-3-billion-in-2019

Heart Failure

Desperate need for new effective treatments to stabilise & reverse heart degeneration

What is Heart Failure?

- Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood through to meet the body's needs for blood and oxygen. The added stress on the heart progressively remodels its structure furthering its degeneration.

Why Focus on Heart Failure?

- Heart failure's 5 year mortality rate is high, exceeding 50%.
- **There are currently no treatments available to stop or reverse the progression of Heart failure**
- Leading treatments have come off patent, driving Big Pharma to find new effective treatments
- **Novel MoA:**
  - PPS is the inhibitor of ADAMTS4 versicanase, a key enzyme involved in the degenerative process in heart failure

Addressable market for Heart Failure:



Estimated number of people who suffer from Heart failure worldwide[2]

US$18+ Billion

Size of the therapeutic market for Heart failure[3]

1. Forbes – The best selling drugs since 1996 (2012) 2. *Heart failure: preventing disease and death worldwide,* P.Ponikowski et al (2014) 3. Sales of six leading compounds – Figures between 2014 & 2016 - Statins $13.2bn (Research and Markets - Global Statin Market 2015-2016), Clopidogrel bisulphate $1.8bn, Beta-blockers $1.55bn, Ace inhibitors 0.47bn, Aspirin $0.54bn, Vitamin K antagonist $0.5bn (www.pharmacompass.com)

Respiratory Conditions - Hay Fever

Hay fever is a very common condition that is poorly treated at present

What is hay fever (allergic rhinitis)?

- Allergic inflammation of the nasal airways, when an allergen is inhaled by a sensitised individual

Why focus on hay fever?

- Strong need for more effective treatment options
  - **More than 50% of patients are dissatisfied with current medication and 60% have said they would be interested in new treatments[1]**
  - Long term use of corticosteroids proven to be harmful to certain sufferers
- Clear need for safer, superior and cheaper treatments
- Hay fever associated with growing economic burden
- **June 2017 Phase 2b hay fever clinical trial top line data missed end-point – final trial report being independently analysed**
- **PPS pre-clinical data was overwhelmingly positive and supports further investigation**
- **Potential for use in COPD and Allergic Asthma**

Addressable market for hay fever:

600 MILLION

Estimated number of people who suffer from hay fever worldwide[2]

US$11+ Billion

size of the therapeutic market for hay fever in 2014[3]

Source:
1. 2005 survey conducted by Asthma and Allergy Foundation of America
2. Mullol J, et al. (2008)
3. Visiongain: Allergic Rhinitis Drugs Market Forecast 2015-2025

IP Protection

Multi-faceted IP protection increases barriers to entry for potential competitors

Valuable patent portfolio

- Paradigm has patent protection because it is using PPS for new indications
- Minimum life on patents is 2030 and beyond for more recent patents - i.e. 2035
- Patents granted for specific indications
- Established regulatory exclusivity and trademarks
- Patent applications for Ross River virus and Chikungunya virus
- Global patent for Heart Failure indication
- Assessing additional patent applications

Secure manufacturing and supply

- Exclusive 20 year supply agreement with bene PharmaChem[1]
- bene pharmaChem makes the only FDA-approved form of PPS
- Manufacturing methods are a well kept trade secret
- Reduces risks associated with manufacturing and supply



Note:

1. bene pharmaChem is a private company located in Germany and manufactures the only officially approved and clinically tested medicinal PPS in the USA, Europe and Australia

Peer Comparison

Attractive investment given low risk development and large market opportunity

- Paradigm appears undervalued compared to similar stage, drug repurposing peers given its platform for successful development, secure industrial scale manufacturing and the size of its addressable markets

Peer	Ticker and exchange	Market cap (A$m)	Rationale	Clinical stage of key product	Addressable market size
Medical Developments International	MVP.ASX	372	Developing new markets and applications for Penthrox, recent focus on respiratory diseases, significant manufacturing IP	Commercialisation	US$1.5bn+
starpharma	SPL.ASX	507	Commercialising an old technology of synthetic branching polymers (dendrimers), with lead product VivaGel in Phase III trials	Phase III & commercialisation	US$3bn+
AXSOME THERAPEUTICS	AXSM.NASDAQ	148	Developing novel therapies for the management of central nervous system disorders, focusing on treatment of BMEL	Phase III	US$2.5bn+[2]
verona pharma	VRP.LN	241	Focused on commercialising an old compound for respiratory diseases, with dual inhibition of key enzymes	Phase I/II(a)	US$12bn+[3]
paradigm BIOPHARMA	PAR.ASX	38	Focused on the clinical development of PPS as a multi-target treatment for complex conditions, such as BMEL/OA, AV & AR	Multiple Phase II(a)	US$37bn+[4]

Source: Bloomberg, company filings

1. Market data as at 01 November 2017, exchange rates of AUDGBP 0.59 and AUDUSD 0.77
2. Based on BMEL addressable market size, excludes CRPS addressable market due to lack of available information and thus likely understates true market size
3. Only includes the market size for COPD which is US$12b+, excludes market sizes for other respiratory disease indications
4. Includes AR market US$11bn+ and OA/BMEL market US$8bn+ & $0.5bn for viral arthritis ,excludes COPD addressable market size of US$12bn+ and Asthma addressable market size of US$15bn+ and Heart failure Figures between 2014 & 2016 - Statins $13.2bn (Research and Markets - Global Statin Market 2015-2016), Clopidogrel bisulphate $1.8bn, Beta-blockers $1.55bn, Ace inhibitors 0.47bn, Aspirin $0.54bn, Vitamin K antagonist $0.5bn (www.pharmacompass.com)

Global Big Pharma Interest

Recent transactions highlight big pharma interest in BMEL/OA, Heart failure and IBD

Date ↓	Target	Acquirer	Deal value (US$)	Relevance
Jul - 17	Galápagos	SERVIER	**$346m**	▪ Galapagos licensed GLPG1972, a potential disease-modifying oral therapy for osteoarthritis to Servier ▪ GLPG1972 is a potent and highly selective inhibitor of ADAMTS-5.
Mar-17	Protagonist Therapeutics	janssen PHARMACEUTICAL COMPANIES OF Johnson & Johnson	**$990m**	▪ Protagonist Therapeutics' lead compound PTG-200 is a first-in-class, oral interleukin-23 receptor antagonist for the treatment of Inflammatory Bowel Disease
Nov-16	TissueGene, Inc. Cell Technologies		**$434m**	• TissueGene, Inc. Licensed the rights for its degenerative osteoarthritis drug Invossa to Japan's Mitsubishi Tanabe Pharma
Nov-15	Cardioxyl PHARMACEUTICALS	Bristol-Myers Squibb	**$1.8Bn (inc $1.5Bn milestones)**	▪ Bristol-Myers Scquibb acquired Cardioxyl to attain the intravenous CXL-1427, which claims to boost heart muscle and vascular function.
May-13	KNEE CREATIONS	ZIMMER BIOMET	**Undisclosed**	▪ Zimmer Biomet acquired Knee Creations for its Subchondroplasty procedure, designed to treat BMEL

Source: Bloomberg, company filings

Share Price Catalysts

Upcoming milestones should drive strong shareholder returns

ACL/BMEL **OA/BMEL** *Phase 2 trials*	▪ Phase 2a open label trial for BMEL with ACL injuries ▪ OA with BMEL RWE results (second 25 patients followed by 2 x 25 patients over year) ▪ Recruit Phase 2b placebo controlled OA clinical trial (100 patients) with **trial results Read Out targeted for end CY2018 / early CY2019** ▪ Additional high Profile sporting identities (such as Andrew Walker, Carlton) treated with PPS under SAS program
ALPHAVIRUSES *Phase 2 Trials*	▪ Completion of RRv Phase 2a clinical trial (24 patients) – **Results Read Out Mid CY2018** ▪ Potential to partner with US DoD on CHIKV treatments and trials ▪ Initiation of CHIKV Phase 2a clinical trial
IL-1RA Peptide *Auto-immune, oncology cancer cachexia*	▪ Reformulation into oral administration ▪ Partner with big Pharma ▪ Progress pilot human clinical trials (TBD)
HAY FEVER	▪ Analysis of Phase 2 results and determine reformulation ▪ Explore formulations for COPD and Allergic Asthma ▪ Potential to JV or co-fund future development
CORPORATE OPPORTUNITIES *Potential partners*	▪ Demonstrated interest from major pharmaceuticals companies in treatments for OA, BMEL, Respiratory, Heart Failure and Alpha Virus' & IL-1 RA peptide ▪ Partnership with world-class manufacturers
EXPANSION *Market share*	▪ Expansion of BMEL market into OA and other joint pain indications ▪ Progress and potentially partner IL-1RA peptide ▪ Progress Alphavirus and Heart Failure ▪ Develop new IP and corporate opportunities in new indications

Contacts

Office

Level 2, 517 Flinders Lane,
Melbourne, VIC, 3000
info@paradigmbiopharma.com

Managing Director & CEO

Paul Rennie - prennie@paradigmbiopharma.com

Chief Scientific Officer

Dr Ravi Krishnan – rkrishnan@paradigmbiopharma.com

Corporate Advisor

Baker Young Stockbrokers Ltd

Dirk van Dissel – dvandissel@bakeryoung.com.au

Analyst – Baker Young Stockbrokers

Alastair Murray – amurray@bakeryoung.com.au